Revolution Medicines Down Over 17%, on Pace for Largest Percent Decrease Since October 2023 -- Data Talk

Dow Jones01-27

Revolution Medicines, Inc. (RVMD) is currently at $97.12, down $20.52 or 17.44%

 

--Would be lowest close since Jan. 6, 2026, when it closed at $79.85

--On pace for largest percent decrease since Oct. 23, 2023, when it fell 34.38%

--Currently down two consecutive days; down 18.26% over this period

--Worst two day stretch since the two days ending Oct. 24, 2023, when it fell 24.85%

--Up 21.93% month-to-date; on pace for best month since Nov. 2025, when it rose 32.15%

--Up 21.93% year-to-date

--Down 21.22% from its all-time closing high of $123.27 on Jan. 15, 2026

--Up 138.44% from 52 weeks ago (Jan. 27, 2025), when it closed at $40.73

--Down 21.22% from its 52-week closing high of $123.27 on Jan. 15, 2026

--Up 211.97% from its 52-week closing low of $31.13 on April 8, 2025

--Traded as low as $92.50; lowest intraday level since Jan. 7, 2026, when it hit $79.94

--Down 21.36% at today's intraday low; largest intraday percent decrease since Oct. 23, 2023, when it fell as much as 44.8%

 

All data as of 11:10:35 AM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

January 26, 2026 11:15 ET (16:15 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment